Hostname: page-component-cd9895bd7-mkpzs Total loading time: 0 Render date: 2024-12-28T18:21:47.514Z Has data issue: false hasContentIssue false
  • English
  • Français

An analysis of infection control of varicella-zoster virus infections in Addenbrooke's Hospital Cambridge over a 5-year period, 1987–92

Published online by Cambridge University Press:  15 May 2009

T. G. Wreghitt ,
J. Whipp ,
C. Redpath  and
W. Hollingworth
T. G. Wreghitt
Affiliation:
Clinical Microbiology & Public Health Laboratory, Addenbrooke's HospitalCambridge CB2 2QW, UK
J. Whipp
Affiliation:
Infection Control Nurse, Addenbrooke's HospitalCambridge CB2 2QW
C. Redpath
Affiliation:
Infection Control Nurse, Addenbrooke's HospitalCambridge CB2 2QW
W. Hollingworth
Affiliation:
Department of Community Medicine, Institute of Public Health, University of Cambridge, Forvie Site, Robinson Way, Cambridge CB2 2SR
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

This prospective study analyses infections with varicella-zoster virus (VZV) in Addenbrooke's Hospital, Cambridge during 1987–92 and examines the spread of infection. In total, 93 patients and staff experienced VZV infection. Twenty-one patients had varicella and 49 experienced zoster. None of 101 patients and 1 of 625 staff members in contact with varicella cases acquired infection. By contrast, 2 of 227 patients, and 5 of 1039 staff in contact with zoster cases acquired varicella. One out of 28 (3·6%) VZV antibody-negative patients and staff in contact with varicella acquired infection, compared with 5 out of 29 (17·2%) VZV antibody-negative patients and staff in contact with zoster. Thus, zoster was found to be a more frequent cause of nosocomial infection than varicella. Fourteen members of staff had VZV infection during the study period. One of 99 patients and none of 389 staff members in contact with these cases developed varicella. The cost of dealing with infection control for VZV infections in our hospital is estimated to be £714 per patient case and a total of £13204 per year.

Type
Research Article
Information
Epidemiology & Infection , Volume 117 , Issue 1 , August 1996 , pp. 165 - 171
Copyright
Copyright © Cambridge University Press 1996

References

1.Breuer, J, Jeffries, DJ. Control of viral infections in hospitals. J Hosp Infect 1990; 16: 191–21.Google Scholar
2.Miller, E, Marshall, R, Vurdien, J. Epidemiology, outcome and control of varicella-zoster infection. Rev Med Micro 1993; 4: 222–30.Google Scholar
3.Miller, E, Vurdien, J, Farrington, P. Shift in age in chickenpox. Lancet 1993; 341: 308–9.CrossRefGoogle ScholarPubMed
4.Joseph, CA, Noah, ND. Epidemiology of chickenpox in England and Wales, 1967–85. B Med J 1988; 296: 673–6.Google Scholar
5.Ellis, ME, Neal, KR, Webb, AK. Is smoking a risk factor for pneumonia in adults with chickenpox? B Med J 1987; 294: 1002.CrossRefGoogle ScholarPubMed
6.Straus, SE, Ostrove, JM, Inchauspe, G, et al. Varicella-zoster virus infections: Biology, natural history, treatment and prevention. Ann Intern Med 1988; 108: 221–37.CrossRefGoogle Scholar
7.Kangro, HO, Harper, DR. Varicella Zoster. In: Zuckerman, AJ, Banatvala, JE, Pattison, JR, eds. Principles and practice of clinical virology. Chichester: John Wiley and Sons, 1995; 37–68.Google Scholar
8.Bradley, JR, Wreghitt, TG, Evans, DB. Chickenpox infections in adult renal transplant recipients. Nephrol Dial Trans 1987; 1: 242–5.Google Scholar
9.Quinnan, GV, Masur, H, Rook, AH, et al. Herpes virus infections in the acquired immunodeficiency syndrome. J Amer Med Ass 1984; 252: 72–7.Google Scholar
10.Miller, E, Cradock-Watson, JE, Ridehalgh, KS. Outcome in newborn babies given anti-varicella-zoster immunoglobulin after perinatal maternal infection with varicella-zoster virus. Lancet 1989; ii: 371–3.CrossRefGoogle Scholar
11.Leclair, J, Zaia, JA, Levin, MJ, Congdon, RG, Goldman, DA. Airborne transmission of chickenpox in a hospital. New Engl J Med 1980; 302: 450–3.CrossRefGoogle ScholarPubMed
12.Weber, DJ, Rutala, WA, Parhan, C. Impact and costs of varicella prevention in a University Hospital. Amer J Publ Health 1988; 78: 19–23.CrossRefGoogle ScholarPubMed
13.Krasinski, K, Holzman, RS, La Couture, R, Florman, A. Hospital experience with varicella-zoster virus. Infect Control 1986; 7, 312–6.CrossRefGoogle ScholarPubMed
14.Wreghitt, TG, Tedder, RS, Nagington, J, Ferns, RB. Antibody assays for varicella-zoster virus. Comparison of competitive ELISA, competitive RIA, complement fixation and indirect immunofluorescence assays. J Med Virol 1984; 13: 361–70.CrossRefGoogle ScholarPubMed
15.Murray, A, Kangro, HO, Heath, RB. Screening hospital staff for antibodies to varicella-zoster virus. Lancet 1990; ii: 192.CrossRefGoogle Scholar
16.Wreghitt, TG, Whipp, PJ, Bagnall, J. Transmission of chickenpox to two intensive care unit nurses from a liver transplant patient with zoster. J Hosp Infect 1992; 20: 125.Google Scholar
17.Meurisse, V, Miller, E, Kensit, J. Varicella in maternity units. Lancet 1990; i: 1100–1.Google Scholar
18.Gershon, A, Steinberg, S, LaRussa, P, Oh, P, Gelb, L and the NIAID varicella vaccine collaborative study group. Live attenuated varicella vaccine: use in healthy adults. Pediatr Res 1987; 21: 325A.CrossRefGoogle Scholar
19.Evans, EB, Pollock, TM, Cradock-Watson, JE, Ridehalgh, MKS. Human anti-chickenpox immunoglobulin in the prevention of chickenpox. Lancet 1980; i: 354–6.Google Scholar